The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate,
improves the outcome of patients with brain hemorrhage.
The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of
sufficient promise to improve outcome before pursuing a larger clinical trial to examine its
effectiveness as a treatment for intracerebral hemorrhage.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Columbia University Duke University Hartford Hospital Henry Ford Hospital Hopital de l'Enfant-Jesus Johns Hopkins University Loyola University Massachusetts General Hospital Medical University of South Carolina Mount Sinai Hospital, New York National Institute of Neurological Disorders and Stroke (NINDS) New York University Langone Medical Center NYU Langone Health Ohio State University Oregon Health and Science University Rhode Island Hospital Rush University Medical Center St. Joseph's Hospital and Medical Center, Phoenix Stanford University The University of Texas Health Science Center, Houston University Hospitals Cleveland Medical Center University of Alberta University of Calgary University of California, San Francisco University of Florida University of Iowa University of Massachusetts, Worcester University of North Carolina University of Pennsylvania University of Washington Weill Medical College of Cornell University Yale New Haven Health System Center for Healthcare Solutions